Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyper-CVAD and Dasatinib in Ph+ or BCR-ABL+ ALL
NCT00390793Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2006
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute lymphoblastic leukemia (ALL), Chronic Myeloid Leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00390793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390793.